Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Clinical trial NCT06130540 · COMPLETED

Trial details

NCT number: NCT06130540
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Giant Cell Arteritis Polymyalgia Rheumatica

Start date: 2024-03-27
Primary completion: 2025-03-12
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.